A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 536,400 shares of ITOS stock, worth $3.89 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
536,400
Previous 559,600 4.15%
Holding current value
$3.89 Million
Previous $8.3 Million 34.06%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$10.09 - $17.97 $234,088 - $416,904
-23,200 Reduced 4.15%
536,400 $5.48 Million
Q2 2024

Aug 09, 2024

SELL
$10.33 - $18.09 $1.63 Million - $2.85 Million
-157,700 Reduced 21.99%
559,600 $8.3 Million
Q1 2024

May 13, 2024

BUY
$9.89 - $13.64 $181,976 - $250,976
18,400 Added 2.63%
717,300 $9.78 Million
Q4 2023

Feb 13, 2024

BUY
$8.57 - $11.06 $2.61 Million - $3.37 Million
304,900 Added 77.39%
698,900 $7.65 Million
Q3 2023

Nov 14, 2023

SELL
$10.95 - $14.6 $210,240 - $280,320
-19,200 Reduced 4.65%
394,000 $4.31 Million
Q2 2023

Aug 11, 2023

BUY
$12.93 - $18.05 $1.08 Million - $1.5 Million
83,300 Added 25.25%
413,200 $5.47 Million
Q1 2023

May 12, 2023

BUY
$13.02 - $22.62 $166,656 - $289,536
12,800 Added 4.04%
329,900 $4.49 Million
Q4 2022

Feb 13, 2023

SELL
$17.77 - $21.6 $1.35 Million - $1.64 Million
-75,800 Reduced 19.29%
317,100 $6.19 Million
Q3 2022

Nov 14, 2022

BUY
$18.6 - $27.25 $1.13 Million - $1.65 Million
60,600 Added 18.24%
392,900 $7.49 Million
Q2 2022

Aug 12, 2022

BUY
$16.57 - $35.1 $3.28 Million - $6.95 Million
198,100 Added 147.62%
332,300 $6.85 Million
Q1 2022

May 13, 2022

BUY
$31.92 - $47.45 $3.23 Million - $4.8 Million
101,100 Added 305.44%
134,200 $4.32 Million
Q4 2021

Feb 11, 2022

BUY
$26.23 - $47.86 $868,213 - $1.58 Million
33,100 New
33,100 $1.54 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $258M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.